Alpine Immune Sciences Announces Proposed Public Offering
06 11월 2023 - 8:00PM
Business Wire
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage
immunotherapy company focused on developing innovative treatments
for autoimmune and inflammatory diseases, today announced that it
has commenced an underwritten public offering of $150 million of
shares of its common stock pursuant to its existing shelf
registration statement. It is expected that the underwriters of the
offering will be granted an option for a period of 30 days to
purchase up to an additional $22.5 million of shares of common
stock at the public offering price, less the underwriting discounts
and commissions. All shares of common stock to be sold in the
proposed offering will be sold by Alpine. The offering is subject
to market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Morgan Stanley, TD Cowen and Leerink Partners are acting as
joint book-running managers for the proposed public offering. RBC
Capital Markets is acting as a bookrunner and Oppenheimer & Co.
and H.C. Wainwright & Co. are acting as co-lead managers for
the proposed public offering.
A shelf registration statement relating to the securities
offered in the proposed public offering described above was filed
with the Securities and Exchange Commission (SEC) on April 28, 2023
and declared effective by the SEC on May 9, 2023. The offering will
be made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus,
when available, may also be obtained by contacting Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, New York 10014, by telephone: 1-866-718-1649,
or by email at prospectus@morganstanley.com; Cowen and Company,
LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at
(833) 297-2926, or by email at Prospectus_ECM@cowen.com; Leerink
Partners LLC, Attention: Syndicate Department, 53 State Street,
40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext.
6105, or by email at syndicate@leerink.com; RBC Capital Markets,
Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New
York, NY 10281, by telephone at (877) 822-4089, or by e-mail at
equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are not based on historical fact and include statements
regarding the anticipated public offering. These forward-looking
statements are based on current assumptions that involve risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from those
expressed or implied by such forward-looking statements. These
risks and uncertainties, many of which are beyond our control,
include, but are not limited to, uncertainties related to market
conditions and the completion of the proposed public offering on
the anticipated terms or at all, as well as the other risks
identified in our filings with the SEC. These forward-looking
statements speak only as of the date hereof and we assume no
obligation to update these forward-looking statements, and readers
are cautioned not to place undue reliance on such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106064132/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024